Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
Sponsor: Vertex Pharmaceuticals Incorporated
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deutivacaftor (D-IVA) with or without tezacaftor (TEZ) in healthy subjects.
Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2026-02-25
Completion Date
2027-06-26
Last Updated
2026-09-23
Healthy Volunteers
Yes
Conditions
Interventions
VX-272
Suspension for Oral Administration.
Placebo
Suspension for Oral Administration.
Tezacaftor
Tablet for oral administration.
Deutivacaftor
Tablet for oral administration.
Locations (1)
Celerion - Tempe
Tempe, Arizona, United States